ArticleHuman genomics2020
Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites.
Article in Human genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02293096 (Pharmacogenetic Prediction of Metoprolol Effectiveness), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetic Prediction of Metoprolol Effectiveness
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Harnessing the gut microbiome for precision therapeutics in heart failure.Frontiers in pharmacology · 2026Review
- Intestinal congestion-driven gut dysbiosis: a cross-disease hemodynamic mechanism in liver cirrhosis and heart failure.Journal of translational medicine · 2025Article
- Review
- Pharmacometabolomics Detects Various Unreported Metoprolol Metabolites in Urine of (Potential) Living Kidney Donors and Kidney Transplant Recipients.Clinical pharmacokinetics · 2025Article
- Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease.Microbiome · 2025Article
- The gut-heart axis: a review of gut microbiota, dysbiosis, and cardiovascular disease development.Annals of medicine and surgery (2012) · 2025Review
- Enhancing photocatalytic degradation of beta-blocker drugs using TiOScientific reports · 2024Article
- Review
- Selected widely prescribed pharmaceuticals: toxicity of the drugs and the products of their photochemical degradation to aquatic organisms.Journal of applied biomedicine · 2024Review
- Oral Cardiac Drug-Gut Microbiota Interaction in Chronic Heart Failure Patients: An Emerging Association.International journal of molecular sciences · 2024Review
- Microbial influence on blood pressure: unraveling the complex relationship for health insights.Microbiome research reports · 2024Article
- The gut microbiome and hypertension.Nature reviews. Nephrology · 2023Review
- Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer.NPJ precision oncology · 2022Article
- Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.Metabolites · 2022Article
- Article
- Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.Frontiers in medicine · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
introductionMetoprolol succinate is a long-acting beta-blocker prescribed for the management of hypertension (HTN) and other cardiovascular diseases. Metabolomics, the study of end-stage metabolites of upstream biologic processes, yield insight into mechanisms of drug effectiveness and safety. Our aim was to determine metabolomic profiles associated with metoprolol effectiveness for the treatment of hypertension.
methodsWe performed a prospective pragmatic trial (NCT02293096) that enrolled patients between 30 and 80 years with uncontrolled HTN. Patients were started on metoprolol succinate at a dose based upon systolic blood pressure (SBP). Urine and blood pressure measurements were collected weekly. Individuals with a 10% decline in SBP or heart rate (HR) were considered responsive. Genotype for the CYP2D6 enzyme, the primary metabolic pathway for metoprolol, was evaluated for each subject. Unbiased metabolomic analyses were performed on urine samples using UPLC-QTOF mass spectrometry.
resultsUrinary metoprolol metabolite ratios are indicative of patient CYP2D6 genotypes. Patients taking metoprolol had significantly higher urinary levels of many gut microbiota-dependent metabolites including hydroxyhippuric acid, hippuric acid, and methyluric acid. Urinary metoprolol metabolite profiles of normal metabolizer (NM) patients more closely correlate to ultra-rapid metabolizer (UM) patients than NM patients. Metabolites did not predict either 10% SBP or HR decline.
conclusionIn summary, urinary metabolites predict CYP2D6 genotype in hypertensive patients taking metoprolol. Metoprolol succinate therapy affects the microbiome-derived metabolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.